GlassScriptPhysician profile
Maria Diaz
NPI 1205256237
$1,868.50
in general payments reported to CMS, 2019-2025
19 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $728 · 2022: $473 · 2023: $307 · 2024: $133 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.50 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $325.64 | 2022-2025 | |
| Pfizer INC. | $266.50 | 2021-2024 | |
| Evofem Biosciences, INC. | $144.53 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $127.41 | 2021-2024 | |
| Agile Therapeutics, INC. | $113.92 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $91.69 | 2021-2022 | |
| Myovant Sciences INC. | $74.15 | 2021-2022 | |
| Hologic Sales and Service, LLC | $49.49 | 2022-2023 | Aptima |
| Exeltis, USA INC. | $45.66 | 2021-2023 | Slynd |
| Shield Therapeutics INC | $31.39 | 2023 | Accrufer |
| Astellas Pharma US INC | $24.63 | 2024 | Veozah |
| Coopersurgical, INC. | $24.05 | 2023 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $20.54 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $20.54 | 2025 | Zurzuvae |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $18.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.80 | 2021 | |
| Millicent US INC | $13.55 | 2025 | Femlyv |
| Lupin INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.